Market Cap 91.47B
Revenue (ttm) 8.41B
Net Income (ttm) 2.90B
EPS (ttm) N/A
PE Ratio 32.86
Forward PE N/A
Profit Margin 34.50%
Debt to Equity Ratio 0.00
Volume 374,800
Avg Vol 120,502
Day's Range N/A - N/A
Shares Out 3.29B
Stochastic %K 47%
Beta 0.63
Analysts Strong Sell
Price Target N/A

Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 81 3 3281 6611
Fax: 81 3 3281 6607
Address:
Nihonbashi Mitsui Tower, Reception12F 1-1 Nihonbashi-Muromachi 2-chome, Chuo, Japan
Latest News on CHGCY
No data available.